Jefferies & Company
JEF
$45.84
-0.28%
Jefferies Financial Group Inc. is a full-service investment banking and capital markets firm operating in the Financial Services sector, primarily serving the North American middle market through advisory, underwriting, sales and trading, and asset management services. Distinct from bulge-bracket universal banks, Jefferies has built its identity as the preeminent independent middle-market investment bank, steadily capturing market share from larger competitors over the past decade since its transformative 2013 merger with Leucadia. The current investor narrative centers on whether Jefferies is the cleanest pure-play beneficiary of a Wall Street investment banking recovery, with recent Zacks coverage highlighting that IB gains are concentrated among advisory-heavy firms like Jefferies while universal banks lag. However, this bullish thesis is being tested by a sharp stock decline of roughly 27% year-over-year, raising questions about whether the market is pricing in cyclical peak concerns, elevated compensation costs, or simply a rotation away from capital markets exposure.…
JEF
Jefferies & Company
$45.84
Related headlines
Investment Opinion: Should I buy JEF Today?
The synthesized recommendation is Hold with a bias toward accumulating on weakness. The core thesis is that Jefferies is a high-quality, well-managed middle-market investment bank trading at a deep discount to book value (1.16x) and forward earnings (10.32x), but the near-term earnings trajectory is uncertain and the stock is in a clear downtrend. The analyst consensus rating of 'buy' with an average target of $55.67 implies 21.1% upside, but the wide target range ($47–$71) and recent UBS downgrade suggest that the recovery timeline is highly uncertain.
Supporting evidence for a constructive view includes: (1) the forward PE of 10.32x is well below the trailing PE of 19.43x, implying a significant earnings recovery that consensus expects; (2) the P/B ratio of 1.16x is near the low end of its historical range (0.72x–1.67x) and at a 20–50% discount to bulge-bracket peers; (3) trailing twelve-month free cash flow is robust at $1.78 billion, and the dividend yield of 3.05% provides income support; (4) the Q3 2026 net margin improved to 12.01% from 8.69% a year earlier, showing cost discipline. However, these positives are offset by a 23.58% YoY revenue decline, a trailing EPS of just $0.058, and a stock that has underperformed the S&P 500 by over 42 percentage points over the past year.
The biggest risks that could invalidate the thesis are: (1) a continued slowdown in investment banking activity that forces downward revisions to the $4.998 forward EPS estimate; (2) a breakdown below the 52-week low of $35.53, which would signal a deeper bear market; and (3) elevated compensation costs or regulatory changes that compress margins. The rating would upgrade to Buy if the stock stabilizes above $50 and forward estimates are maintained, or if P/B falls below 1.0x. It would downgrade to Sell if revenue growth decelerates further (e.g., another quarter of >20% YoY decline) or if the dividend is cut. Relative to its history and peers, JEF appears undervalued on a book value basis but fairly valued on trailing earnings; the investment case hinges on the realization of forward estimates.
Sign up to view all
JEF 12-Month Price Forecast
The forward-looking view is cautiously neutral: Jefferies offers compelling value on normalized earnings and book value, but the timing of the investment banking recovery is uncertain and the stock's technical trend remains negative. The 10.32x forward PE and 1.16x P/B suggest the market is pricing in a recovery that has yet to appear in reported results, creating both opportunity and risk. Analyst sentiment is moderately bullish, but the wide target spread and recent UBS downgrade indicate disagreement about the pace of improvement. I would upgrade to bullish if the stock reclaims the $55–$57 resistance zone and forward estimates are maintained, or if P/B falls below 1.0x. I would downgrade to bearish if revenue declines accelerate or if the dividend is cut, signaling deeper structural issues.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Jefferies & Company's 12-month outlook, with a consensus price target around $55.67 and implied upside of +21.4% versus the current price.
Average Target
$55.67
0 analysts
Implied Upside
+21.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$47 - $71
Analyst target range
Six analysts cover Jefferies with a consensus recommendation of "buy" and a recommendation mean of 2.33 (where 1 is Strong Buy and 5 is Strong Sell), indicating a moderately bullish but not overwhelmingly enthusiastic stance. The average target price is $55.67, which implies approximately +21.1% upside from the current price of $45.97, suggesting analysts see meaningful value at these levels. The consensus leans constructive, supported by recent institutional ratings showing Oppenheimer maintaining Outperform and Goldman Sachs maintaining Buy as of late September 2026, though Morgan Stanley and BMO Capital remain at Equal Weight and Market Perform respectively, reflecting a split view on the pace of IB recovery.
The target price range spans from a low of $47.00 to a high of $71.00, a spread of $24.00 or approximately 51% of the average target, signaling significant disagreement among analysts about the company's trajectory. The high target of $71.00 implies roughly +54.5% upside and likely assumes a robust IB recovery cycle, multiple expansion back toward 1.5x book, and successful operating leverage on a higher revenue base. The low target of $47.00 implies just +2.2% upside and likely prices in continued margin compression, elevated compensation ratios, and a slower-than-expected deal environment. Notably, UBS downgraded from Buy to Neutral on June 18, 2026, which preceded the stock's sharp decline from the $60s to the $40s, suggesting the downgrade was prescient. The wide target spread combined with the recent downgrade and the stock's high beta of 1.491 indicates elevated uncertainty, and the moderate short ratio of 3.97 suggests that while there is some bearish positioning, it is not at levels that would signal an imminent squeeze.
Bulls vs Bears: JEF Investment Factors
The bear case currently has stronger near-term evidence: JEF is in a clear downtrend, down 27% over the past year and underperforming the S&P 500 by over 42 percentage points, with revenue contracting 23.58% YoY and trailing EPS of just $0.058. However, the bull case rests on forward-looking metrics that are compelling if the IB recovery materializes: a forward PE of 10.32x, a P/B of 1.16x near historical lows, and analyst targets implying 21% upside. The single most important tension is whether the investment banking recovery will accelerate enough to justify forward EPS of ~$5.00, or whether cyclical peak concerns and elevated compensation costs will keep earnings depressed. If forward estimates are achieved, the stock is deeply undervalued; if they are revised downward, the current price may still be too high. The resolution of this debate hinges on deal flow and advisory revenue trends over the next two to three quarters.
Bullish
- Deep Value on Book and Forward Earnings: JEF trades at just 1.16x book value, near the low end of its historical range (0.72x–1.67x) and at a 20–50% discount to bulge-bracket peers that typically command 1.5–2.5x book. With forward EPS estimated at $4.998, the forward PE is only 10.32x, implying the market is pricing in a full earnings recovery that has yet to materialize in reported results.
- Analyst Consensus Sees 21% Upside: Six analysts rate JEF a 'buy' with a mean recommendation of 2.33 and an average target price of $55.67, representing +21.1% upside from the current $45.97. The high target of $71.00 implies +54.5% upside, reflecting confidence in a robust investment banking recovery.
- Strong Cash Generation and Dividend Support: Trailing twelve-month free cash flow is $1.78 billion, and the Q2 2026 quarter alone generated $1.55 billion in FCF, demonstrating the firm's ability to convert earnings to cash during favorable periods. The 3.05% dividend yield, backed by a 52.66% payout ratio, provides a valuation floor and shareholder-friendly capital return.
- IB Recovery Concentrated in Advisory Firms: Recent Zacks coverage highlights that investment banking gains are concentrated among advisory-heavy firms like Jefferies while universal banks lag. Jefferies' Investment Banking segment generated $1.21 billion in Q3 2026, the largest revenue contributor, positioning it as a pure-play beneficiary of a middle-market deal rebound.
Bearish
- Severe Revenue Contraction and Earnings Volatility: Q3 2026 revenue fell 23.58% YoY to $2.22 billion, and the trailing twelve-month EPS is just $0.058 due to a Q4 2025 loss quarter with negative EBITDA of -$1.44 billion. This extreme earnings volatility makes trailing valuation metrics unreliable and raises questions about the sustainability of the recovery.
- Stock in Clear Downtrend, Underperforming Market: JEF has declined 27.11% over the past year and 27.56% YTD, with a 1-month drop of 13.10% versus the S&P 500's +0.59% gain, resulting in a relative strength of -13.69%. The stock sits at just 33.7% of its 52-week range, signaling persistent selling pressure and no durable bottom.
- High Beta Amplifies Downside Risk: With a beta of 1.491, JEF is approximately 49% more volatile than the S&P 500, meaning it would be expected to decline roughly 1.5x as much in a market selloff. The maximum drawdown of -48.81% over the observed period underscores the stock's capacity for severe capital destruction during adverse cycles.
- Elevated Leverage and Modest ROE: The debt-to-equity ratio of 2.25 reflects the inherent leverage of an investment bank, while the ROE of 6.72% is well below the 24.87% reported in the most recent quarterly historical ratio data and below peers that typically generate 10–15% ROE. This suggests capital efficiency is currently depressed.
JEF Technical Analysis
Jefferies is in a clear intermediate-term downtrend despite a brief summer recovery attempt, with the stock posting a 1-year price change of -27.11% and a YTD decline of -27.56%. At the current price of $45.97, the stock sits at just 33.7% of its 52-week range (52-week low of $35.53, 52-week high of $66.60), placing it in the lower third of its annual trading band. This positioning signals that sellers remain in control and the stock has not yet established a durable bottom, though the proximity to the lower range boundary may begin to attract value-oriented buyers. The 6-month change of +10.32% versus the 1-year change of -27.11% reveals a significant divergence, suggesting the most severe damage occurred in late 2025 and early 2026, with a partial stabilization since spring.
Recent momentum has deteriorated sharply, with the 1-month change at -13.10% and the 3-month change at -12.64%, indicating that the summer rally has fully reversed and selling pressure has re-accelerated. This 1-month decline of -13.10% stands in stark contrast to the S&P 500's +0.59% gain over the same period, producing a relative strength of -13.69% and confirming significant underperformance versus the broader market. The stock's peak near $62.81 in late June 2026 followed by a rapid descent to $45.97 represents a drawdown of approximately 26.8% from that interim high, and the failure to hold the $50 psychological level in mid-September suggests momentum remains negative. With a short ratio of 3.97, there is a moderate but not extreme level of bearish positioning that could fuel a squeeze if a positive catalyst emerges.
Key technical support rests at the 52-week low of $35.53, which represents a critical floor approximately 22.7% below the current price; a breakdown below this level would signal a deeper structural bear market and likely trigger accelerated selling. Resistance is established at the 52-week high of $66.60, roughly 44.9% above current levels, and reclaiming even the $55-$57 zone (the July-August consolidation area) would be necessary to signal a trend reversal. The stock's beta of 1.491 means it is approximately 49% more volatile than the S&P 500, implying that in a market selloff, Jefferies would be expected to decline roughly 1.5x as much, which is critical for position sizing and risk management. The maximum drawdown of -48.81% over the observed period underscores the stock's capacity for severe capital destruction during adverse cycles, reinforcing the need for disciplined stop-loss levels.
Beta
1.54
1.54x market volatility
Max Drawdown
-48.8%
Largest decline past year
52-Week Range
$36-$67
Price range past year
Annual Return
-26.6%
Cumulative gain past year
| Period | JEF Return | S&P 500 |
|---|---|---|
| 1m | -17.0% | +0.6% |
| 3m | -13.2% | +3.6% |
| 6m | +4.8% | +14.6% |
| 1y | -26.6% | +15.8% |
| ytd | -27.8% | +13.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JEF Fundamental Analysis
Jefferies' revenue trajectory presents a mixed picture: the most recent quarter (Q3 2026, ending August 31) reported revenue of $2.22 billion, representing a YoY decline of -23.58% versus the $2.91 billion reported in Q3 2025. However, the sequential trend tells a more nuanced story, with revenue declining from $3.41 billion in Q2 2026 to $2.87 billion in Q1 2026 and then to $2.22 billion in Q3, suggesting significant quarterly volatility typical of capital markets businesses. Within the revenue mix, Investment Banking generated $1.21 billion as the largest segment, followed by Interest Revenue at $854 million and Principal Transactions at $489 million, confirming that advisory and underwriting remain the core growth engine. The YoY revenue decline is concerning but may reflect timing of deal closings rather than a structural deterioration, especially given the Zacks narrative of a recovering IB environment.
Profitability remains intact but is compressing: Q3 2026 net income was $266.8 million with a net margin of 12.01%, down from the 8.69% net margin in Q3 2025 despite the lower revenue base, though the current quarter benefited from a lower effective tax rate of 24.78%. Gross margin in Q3 2026 was exceptionally high at 91.26%, but this metric is less meaningful for investment banks where compensation is the dominant cost; operating margin stood at 15.80%, and EBITDA was $394.3 million with an EBITDA ratio of 17.75%. The quarterly EPS of $1.12 (diluted $1.08) compares favorably to the $1.04 reported in Q3 2025, indicating that cost management and share count discipline are partially offsetting revenue headwinds. However, the trailing twelve-month EPS of just $0.058 reflects the drag from the Q4 2025 loss quarter (EBITDA of -$1.44 billion), which severely distorts annual profitability metrics.
Jefferies' balance sheet reflects the inherent leverage of an investment bank, with a debt-to-equity ratio of 2.25 and a current ratio of 2.43 indicating adequate short-term liquidity. Free cash flow on a trailing twelve-month basis is robust at $1.78 billion, and the Q2 2026 quarter alone generated $1.55 billion in FCF, demonstrating the firm's ability to convert earnings to cash during favorable periods. However, cash flow is highly volatile: Q1 2026 saw negative operating cash flow of -$1.74 billion due to working capital swings, and Q1 2025 was even worse at -$2.67 billion, highlighting the seasonal and mark-to-market-driven nature of cash generation. The ROE of 6.72% is modest for a financial firm and well below the 24.87% reported in the most recent quarterly historical ratio data, suggesting that the trailing metric is depressed by the Q4 2025 loss; the dividend yield of 3.05% with a payout ratio of 52.66% indicates a shareholder-friendly capital return policy that may be difficult to sustain if earnings remain under pressure.
Quarterly Revenue
$2.2B
2026-08
Revenue YoY Growth
-23.6%
YoY Comparison
Gross Margin
91.3%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JEF Overvalued?
Because Jefferies reported positive trailing net income (EPS of $0.058, though barely positive), the PE ratio is the appropriate primary metric, and the trailing PE of 19.43x appears elevated relative to the forward PE of 10.32x. This dramatic gap between trailing and forward multiples implies the market expects a substantial earnings recovery, with consensus estimated EPS of $4.998 for the forward period versus the trailing $0.058, a roughly 86x increase that reflects the normalization of earnings after the Q4 2025 loss quarter. The forward PE of 10.32x is the more economically meaningful metric for a cyclical financial, and it suggests the stock is priced for a recovery that has not yet fully materialized in reported results. The PEG ratio of -3.99 is not meaningful given the negative earnings growth rate in the trailing period.
On a price-to-book basis, Jefferies trades at 1.16x, which is modest for an investment bank and compares favorably to the sector's typical range of 1.0x to 2.0x for diversified capital markets firms. The PS ratio of 1.13x and EV/Sales of -1.59 (negative due to the net cash position in the enterprise value calculation) suggest the market is not assigning a premium to Jefferies' revenue stream. Compared to bulge-bracket peers that often trade at 1.5x to 2.5x book, Jefferies' 1.16x P/B represents a discount of roughly 20-50%, which may be justified by its smaller scale, middle-market focus, and lower ROE of 6.72% versus peers that typically generate 10-15% ROE. The dividend yield of 3.05% is above the sector average and provides a valuation floor, though the payout ratio of 52.66% leaves limited room for error.
Historically, Jefferies' PE ratio has ranged from a low of 6.74x (Q1 2022) to a high of 150.35x (Q2 2023), with the current trailing PE of 19.43x sitting in the middle of that wide band but above the 5-year median of approximately 15-16x. The P/B ratio of 1.16x is near the lower end of its historical range, which has spanned from 0.72x (Q3 2022) to 1.67x (Q4 2024), suggesting the stock is closer to a value opportunity than a momentum trap on a book value basis. However, the elevated trailing PE reflects depressed trailing earnings rather than genuine overvaluation, and if forward estimates of ~$5.00 EPS are achieved, the forward PE of 10.32x would represent a meaningful discount to the broader financial sector. The key risk is that if the IB recovery stalls and forward estimates are revised downward, the stock could re-rate lower despite appearing cheap on normalized earnings.
PE
19.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Jefferies faces significant financial and operational risks stemming from its highly cyclical and volatile earnings profile. The company reported a Q4 2025 loss quarter with negative EBITDA of -$1.44 billion, which dragged trailing twelve-month EPS down to just $0.058 and caused the trailing PE to balloon to 19.43x. Revenue is heavily concentrated in investment banking, which generated $1.21 billion in Q3 2026 but declined 23.58% YoY, exposing the firm to deal-timing risk and market sentiment. The debt-to-equity ratio of 2.25 reflects the inherent leverage of an investment bank, and while the current ratio of 2.43 indicates adequate short-term liquidity, the ROE of 6.72% is modest and well below the 24.87% quarterly historical ratio, suggesting capital efficiency is currently depressed. Additionally, the dividend payout ratio of 52.66% may be difficult to sustain if earnings remain under pressure, potentially threatening the 3.05% yield.
Market and competitive risks are elevated given JEF's high beta of 1.491, which makes it approximately 49% more volatile than the S&P 500 and vulnerable to sharp declines in a market selloff. The stock trades at a premium trailing PE of 19.43x relative to its 5-year median of 15–16x, though this reflects depressed trailing earnings rather than genuine overvaluation. Competitive disruption from bulge-bracket banks and boutique advisory firms could pressure Jefferies' middle-market share, and regulatory headwinds—such as changes in capital requirements or compensation rules—could increase costs. Recent news highlights that IB gains are concentrated among advisory-heavy firms like Jefferies, but this also means the firm is highly sensitive to a slowdown in M&A and underwriting activity. The wide analyst target spread ($47–$71) and the recent UBS downgrade underscore the uncertainty surrounding the pace of recovery.
In a worst-case scenario, a stalled investment banking recovery combined with a broader market downturn could trigger a re-rating toward the 52-week low of $35.53, representing a 22.7% decline from the current price of $45.97. If forward EPS estimates are revised downward—say, to $3.50—the forward PE would rise to 13.1x, still not cheap for a cyclical financial with declining revenue. A breakdown below the $35.53 support level would signal a deeper structural bear market and likely accelerate selling, potentially pushing the stock toward the analyst low target of $47.00 (which is actually above the current price, but in a severe scenario, targets could be cut). Given the maximum drawdown of -48.81%, an investor could lose 35–50% from current levels in an adverse scenario, especially if the Q4 2026 earnings report disappoints and triggers further downgrades.
FAQ
The most severe risk is earnings volatility and cyclicality: Q4 2025 saw a loss quarter with negative EBITDA of -$1.44 billion, and Q3 2026 revenue fell 23.58% YoY. Second, the stock has a high beta of 1.491, making it 49% more volatile than the S&P 500, and it has underperformed the market by over 42 percentage points over the past year. Third, leverage is elevated with a debt-to-equity ratio of 2.25, and the ROE of 6.72% is modest, limiting capital flexibility. Fourth, the dividend payout ratio of 52.66% may be unsustainable if earnings remain under pressure, potentially threatening the 3.05% yield. Finally, competitive and regulatory risks could pressure margins, especially if compensation costs rise or deal activity slows.
Our 12-month forecast assigns a 50% probability to a base case where JEF trades between $52 and $58, supported by a gradual earnings recovery and forward EPS near $5.00. The bull case (25% probability) targets $66.60–$71.00, driven by a robust IB recovery and multiple expansion. The bear case (25% probability) sees a decline to $35.53–$47.00 if earnings disappoint or the market rotates away from cyclicals. The most likely scenario is the base case, which assumes investment banking revenue grows 5–10% sequentially and forward estimates are achieved. Key catalysts include Q4 2026 earnings, M&A activity trends, and Fed rate policy.
JEF appears undervalued on a price-to-book basis at 1.16x, which is near the low end of its historical range (0.72x–1.67x) and at a 20–50% discount to bulge-bracket peers trading at 1.5–2.5x book. The forward PE of 10.32x is also attractive, but it relies on consensus EPS of $4.998, which represents an 86x increase from trailing EPS of $0.058. The trailing PE of 19.43x is above the 5-year median of 15–16x, but this reflects depressed trailing earnings rather than genuine overvaluation. The market is pricing in a significant earnings recovery; if that recovery stalls, the stock could be fairly valued or even overvalued. Overall, the valuation is compelling if forward estimates are met, but carries execution risk.
From a risk/reward perspective, JEF is a reasonable buy for value-oriented investors willing to accept high volatility, but it is not a slam dunk. The stock trades at 1.16x book and 10.32x forward earnings, with analyst targets implying 21.1% upside to $55.67. However, the company just reported a 23.58% YoY revenue decline, trailing EPS is only $0.058, and the stock is down 27% over the past year. The biggest downside risk is a break below the 52-week low of $35.53, which would represent a 22.7% loss from current levels. For investors with a 2–3 year horizon and tolerance for cyclicality, the risk/reward is favorable, but near-term momentum is negative and a catalyst is needed to reverse the trend.
JEF is better suited for long-term investors with a 2–3 year horizon who can tolerate cyclical volatility. The stock's beta of 1.491 and max drawdown of -48.81% make it unsuitable for short-term trading unless one is actively hedging. The dividend yield of 3.05% and low P/B of 1.16x provide some downside support for patient holders, but earnings visibility is low and quarterly results can be highly volatile. A minimum holding period of 18–24 months is recommended to allow the investment banking cycle to recover and forward estimates to materialize. Short-term traders should focus on technical levels: support at $35.53 and resistance at $55–$57.